During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia ...

Jeremy S. Abramson, MD, discusses the significant 2-year follow-up results from the phase 3 STARGLO trial in DLBCL.

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and ...

Jacob E. Berchuck, MD, discusses research on plasma epigenomic profiling in metastatic castration-resistant prostate cancer.

Jamie Jacobs, PhD, provides background on a digital intervention for caregivers of patients undergoing bone marrow transplant.

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse ...

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous ...

The investigational treatment DZD8586 elicited encouraging antitumor activity with manageable toxicity in heavily pretreated ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.

David Andorsky, MD, discusses efficacy and safety findings from the ASC2ESCALATE study of asciminib in chronic myeloid leukemia.